What is thrombocytopenia and why is it talked about in relation to AstraZeneca

What is thrombocytopenia and why is it talked about in relation to AstraZeneca
What is thrombocytopenia and why is it talked about in relation to AstraZeneca

The Vaxzevria vaccine produced by AstraZeneca returned to the center of newspapers after the death of Camilla Canepa, student of 18 years died two weeks after administering the drug. According to what has been learned in the past few hours, the young woman suffered from an autoimmune disease and was taking double hormone therapy.

This discovery could exonerate the anti Covid preparation. It will now be up to the investigators to understand whether the patient has reported her clinical picture to health professionals in the form delivered before administration. L’prevaccinal history, as the health company had declared, it was in fact “negative“.

Camilla Canepa suffered from thrombocytopenia autoimmune, which causes a lowering of the count of platelets inside the blood because these are destroyed by the body itself or their production is inhibited.

More will be needed exams to ascertain the causes of the student’s death, but it is possible to hypothesize that her illness contributed to unleashing the picture that led her to develop atypical thrombosis after the administration of Vaxzevria, for which several neurosurgical interventions were required.

What is autoimmune thrombocytopenia (or thrombocytopenia) and how is it diagnosed

Also note as thrombocytopenia autoimmune O E.T.C it is a rare disease that arises from unknown causes, and in most cases it is asymptomatic.

It emerges after specialist examinations if a reduction in platelet levels below the threshold is detected 150 thousand platelets in a microliter of blood, and an average count of red blood cells and white blood cells.

For the diagnosis it is necessary that thrombocytopenia is detected in several controls, because other factors, such as infections, can influence blood values. It is also important to rule out additional causes of low platelet counts with other tests.

What types of thrombocytopenia exist and how are they classified

The disease can also be temporary, and for this reason three phases are identified, as also explained by Aipit Onlus, the Italian Association of Immune Thrombocytopenic Purpura.

  • ITP of new diagnosis, in the first three months after diagnosis.
  • E.T.C persistent, if it persists for up to one year after diagnosis.
  • E.T.C chronic, if it persists beyond one year after diagnosis.

It can also be contracted in shape primary o in forma secondary. In the latter case it is linked to other pathologies, of which it is an indirect consequence, such as leukemia, myeloma and carcinoma and various autoimmune diseases.

How thrombocytopenia is treated and what severe symptoms it entails

Typically if platelets remain around 50 thousand no particular health problems arise in the patient, who may never present any problems symptoms specific. The most common ones are manifestations bleeding.

The mortality it is very low, and in general it is a clinical picture with which one can live safely also thanks to targeted therapies. In severe cases, removal of the spleen.

It is in this organ that, in pathological conditionsin fact, the antibodies that attack the platelets are produced. The spleen is also a site of the monocyte-macrophage system that eliminates from the blood the cells to which the antibodies bind, which in this case are not recognized as its own.

PREV Altavilla executive president of Italy Air Transport. The Mef: “Trust in the CEO”
NEXT books, husband, son and Jack London